Navigation Links
MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
Date:3/15/2010

HAYWARD, Calif. and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).  

"The filing of the first IND just two years since the inception of MicuRx represents a significant accomplishment for our company. This validates our hybrid business model utilizing China's abundant scientific talent and cost-effective infrastructure coupled with experienced U.S. management guiding discovery and preclinical efforts," said Zhengyu Yuan, Ph.D., president and chief executive officer of MicuRx Pharmaceuticals, Inc. "This IND application has been accepted by the SFDA with Special Review status, and we expect to initiate a clinical trial in 2010."

MRX-I: A Safer Oxazolidinone Antibiotic

MRX-I is a next-generation oral oxazolidinone antibiotic for treating methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) infections. Extensive animal studies have demonstrated that MRX-I cures infections due to Gram-positive bacteria including MRSA and VRE effectively. In addition, preclinical toxicology studies have shown that MRX-I is safe, and MicuRx anticipates a superior therapeutic window for this compound.  

Multi-Drug Resistance: A Growing Global Public Health Crisis

Modern antibiotics have substantially reduced the threat posed by infectious diseases and contributed to a dramatic drop in mortality rates over the past 40 years.  However, pathogenic bacteria resistant to current therapies have evolved over the years and become ubiquitous. The World Health Organization, Centers for Disease Control and the Infectious Disease Society of America have identified multi-drug resistant bacteria as a major public health threat today and into the future. In 2008, more than 65,000 people died of drug-resistant bacteria in the United States. In certain regions, the incidence of drug-resistant MRSA increased almost 70% over the last three years alone. MicuRx's compounds directly address the escalating problem of multi-drug resistant bacteria, with the potential to be used both in hospital and community-based settings.  

About MicuRx Pharmaceuticals, Inc.

MicuRx is discovering and developing novel antibiotics to combat infections due to resistant bacteria. Positioned to capture the benefits of United States research and development expertise together with the high quality, low cost discovery, preclinical and development infrastructure in China, the company has built a pipeline of discovery and development programs for the treatment of Gram-positive bacteria, Gram-negative bacteria and fungal infections. The company has research and development facilities outside San Francisco, CA in the United States and in Shanghai, China.  

SOURCE MicuRx Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.micurx.com

'/>"/>

SOURCE MicuRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
2. Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer
3. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
4. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
5. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
6. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
7. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
8. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
9. Jury Verdict Against Novartis Pharmaceuticals For Retaliating Against Drug Sales Rep Who Took Maternity Leave
10. Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit - A Comprehensive Approach to the Management of Atopic Dermatitis
11. DUSA Pharmaceuticals to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... India , March 24, 2017 Abdominal Aortic Aneurysm Repair ... million by 2022, Globally, registering a CAGR of 5.1% from 2016 to 2022. The ... projected to dominate the market during the study period. ... ... ...
(Date:3/24/2017)... , March 24, 2017 New England Pediatric ... of an award including funding and in-kind service towards ... technology.  "Making blood draws less traumatic ... their whole hospital experience better.  We,re looking forward to ... can help improve care for the kids we treat," ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... Demand Forecast to 2022" report to their offering. ... The global wound care market was worth ... CAGR of 6.7% during 2016-2022 Among the various wound care ... in the global market in 2015. Among the various applications, surgical wound ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... Buzzies parent company, ... 10 for Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her ... April 8. , Project Entrepreneur’s second annual venture competition ignites bold ideas by ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... recently received the CE Certificate of Conformity for the Smart System® 20/20. CE ... exceed the highest industry standards and specifications such as ANSI, ISO and proven ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... and conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, ... packaged with the April edition of American Veterinarian™. , “We look ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... weight management program at Women’s Excellence will help patients lose weight and keep ... exam. The specialists at Women's Excellence will measure BMI, body fat composition, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... epigenetic research products enables researchers to pursue the recent RNA methylation “gold rush” ... . In light of the newfound characteristics of N6-methyladenosine, or m6A , ...
Breaking Medicine News(10 mins):